Yifan Wang
Impact in
- Hepatology top 1%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
Papers in
-
- Extracellular vesicles in disease 11
- CRISPR and Genetic Engineering 6
- Oncology 51
- Cancer Immunotherapy and Biomarkers 15
- Cancer Cells and Metastasis 8
- Co-authors
- Binhua P. Zhou (7 shared papers)Wen Jiang (31 shared papers)Jian Shi (2 shared papers)Xuhua Ying (2 shared papers)Betty Y.S. Kim (19 shared papers)Weiye Deng (17 shared papers)Chenfang Dong (4 shared papers)Jun Yao (2 shared papers)
- Journals
- Clinical Cancer Research (5 papers)Journal of Clinical Oncology (4 papers)Frontiers in Pharmacology (4 papers)Nature Nanotechnology (4 papers)Scientific Reports (4 papers)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Yifan Wang
174 papers receiving 7.1k citations
Yifan Wang's Hit Papers
Peers
Comparison fields: 5 of 157
- Hepatology 773
- Oncology 2.4k
- Cancer Research 1.1k
- Immunology 1.1k
- Molecular Biology 3.0k
Countries citing papers authored by Yifan Wang
This map shows the geographic impact of Yifan Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yifan Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yifan Wang more than expected).
Fields of papers citing papers by Yifan Wang
This network shows the impact of papers produced by Yifan Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yifan Wang. The network helps show where Yifan Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Yifan Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 194 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma Hit paper breakdown → | 2021 | 891 |
| 2 | The Role of Snail in EMT and Tumorigenesis Hit paper breakdown → | 2013 | 713 |
| 3 | 2014 | 382 | |
| 4 | 2012 | 371 | |
| 5 | 2018 | 290 | |
| 6 | Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial Hit paper breakdown → | 2020 | 280 |
| 7 | 2013 | 197 | |
| 8 | 2020 | 187 | |
| 9 | 2005 | 174 | |
| 10 | 2020 | 167 | |
| 11 | Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles Hit paper breakdown → | 2022 | 151 |
| 12 | 2019 | 139 | |
| 13 | 2017 | 138 | |
| 14 | 2013 | 128 | |
| 15 | 2018 | 125 | |
| 16 | 2019 | 116 | |
| 17 | 2017 | 115 | |
| 18 | 2019 | 103 | |
| 19 | 2020 | 98 | |
| 20 | 2019 | 92 |
About Yifan Wang
Yifan Wang is a scholar working on Molecular Biology, Oncology, Surgery, Biomedical Engineering and Immunology, having authored 194 papers that have together received 7.1k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (17 papers), Nanoplatforms for cancer theranostics (17 papers), Cancer Immunotherapy and Biomarkers (15 papers), Immunotherapy and Immune Responses (12 papers), Extracellular vesicles in disease (11 papers), Cancer Cells and Metastasis (8 papers), Lung Cancer Treatments and Mutations (8 papers) and CRISPR and Genetic Engineering (6 papers). The work is most often cited by research in Hepatology (773 citations), Oncology (2.4k citations), Cancer Research (1.1k citations), Immunology (1.1k citations) and Molecular Biology (3.0k citations). Yifan Wang has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Binhua P. Zhou, Wen Jiang, Jian Shi, Xuhua Ying, Betty Y.S. Kim, Weiye Deng, Chenfang Dong, Jun Yao, Steven H. Lin and B. Mark Evers. Their work appears in journals such as Clinical Cancer Research, Journal of Clinical Oncology, Frontiers in Pharmacology, Nature Nanotechnology and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.